August 11, 2026

Testosterone, PCOS, and the Hormonal Pathways to Sarcopenic Obesity in Young Adults

By Dr. Zakira Naureen, Associate Professor, University of Nizwa
Hormones Young Adults Metabolic Health

In Simple Terms

  • Why hormones, not just diet and exercise, shape your muscle-to-fat balance
  • Why falling testosterone in young men with obesity accelerates muscle loss
  • Why PCOS complicates the muscle picture for young women specifically
  • What the evidence actually supports doing about each pathway

Diet and exercise get most of the attention in conversations about sarcopenic obesity, but the endocrine system sets much of the background chemistry that determines whether a young adult's body stores energy as muscle or as fat. Two hormonal pathways illustrate this particularly well: falling testosterone in young men with obesity, and the hormonal profile of polycystic ovary syndrome (PCOS) in young women. Both are common, both are tied to excess adiposity, and both have been proposed as drivers of low muscle mass. The actual evidence, once you look closely at the trials and meta-analyses, turns out to be more specific and more interesting than a simple "low hormone equals low muscle" story.

The Endocrine Feedback Loop Between Fat and Muscle

Sex hormones and muscle tissue interact in both directions. Testosterone and estrogen support muscle protein synthesis and influence how the body partitions fuel between fat and lean tissue, while muscle and fat tissue themselves produce signals that feed back into the hormonal system. In men, adipose tissue increases the conversion of testosterone into estrogen and suppresses the brain's signaling to the testes, while obesity-related inflammation and insulin resistance further dampen testosterone production. In women, conditions marked by androgen excess and insulin resistance, most notably PCOS, are thought to influence muscle protein turnover through similar inflammatory and metabolic channels. This bidirectional relationship is what makes hormones a genuine mechanistic pathway to sarcopenic obesity, not just a marker that happens to move alongside it.

Obesity, Low Testosterone, and Muscle Loss in Young Men

The relationship between body fat and testosterone in men is well established mechanistically. Obese men have around 30% lower total testosterone than lean men, and close to 40% have total testosterone levels below 12 nmol per liter, the lower limit typically reported for healthy young men, according to background research cited in a randomized controlled trial published in BMC Medicine. Part of this reduction comes from lower sex hormone binding globulin, and part comes from adiposity related suppression of the hormonal signaling that drives testosterone production in the testes. Preclinical evidence summarized in the same trial also points to a more direct route: testosterone deficiency appears to promote fat tissue accumulation while reducing muscle building signaling through the androgen receptor pathway, which would help explain why low testosterone and reduced muscle mass tend to travel together in obesity.

What a Randomized Trial Found When Testosterone Was Restored

Mechanism is one thing; a controlled trial testing the hormone directly is stronger evidence. A 56 week randomized, double blind, placebo controlled trial in 100 obese men with low to low normal testosterone (BMI of 30 or higher, total testosterone at or below 12 nmol per liter) combined a structured weight loss diet with either testosterone undecanoate injections or a matching placebo. Both groups lost similar amounts of lean mass during the initial very low energy diet phase, but during the following weight maintenance period the testosterone group regained 3.3 kilograms of lean mass compared with just 0.8 kilograms in the placebo group. By the end of the study, the testosterone group had preserved significantly more lean mass than placebo, a mean adjusted difference of 3.4 kilograms, and also showed greater reductions in fat mass and visceral fat measured by CT scan. In the trial's own words, men on placebo lost both fat and lean mass while dieting, but the weight loss in the testosterone group came almost entirely from fat. This is one of relatively few RCTs to isolate the hormone itself as the intervention rather than simply observing an association, and it supports a real, not just correlational, role for testosterone in preserving muscle during weight loss in obese men.

It is worth being precise about who this trial studied: the median participant age was 53, not the 18 to 35 range this site focuses on. The mechanism, however, including obesity driven suppression of testosterone and its consequences for body composition, begins well before midlife, since the underlying drivers (excess adiposity, inflammation, insulin resistance) are increasingly present in younger men too.

PCOS: A Parallel but Different Hormonal Pathway in Young Women

PCOS is the most common endocrine disorder in reproductive age women and is closely associated with excess androgen, insulin resistance, and chronic low grade inflammation, all mechanisms already linked to skeletal muscle loss in other contexts. A case control study published in BMC Endocrine Disorders examined 68 women with PCOS aged 18 to 35 alongside 60 healthy age matched controls using dual energy X-ray absorptiometry. The results were striking: 53% of the women with PCOS met criteria for sarcopenic obesity (appendicular skeletal muscle mass two standard deviations below the control mean, combined with body fat above 35%), and median appendicular skeletal muscle mass was 23.8% in the PCOS group versus 30.4% in controls. Within the PCOS group, the percentage of muscle mass correlated negatively with insulin resistance (HOMA-IR), with C-reactive protein, and with glycosylated hemoglobin, and positively with vitamin D, a pattern consistent with the idea that insulin resistance and inflammation, both hallmark features of PCOS, actively erode relative muscle mass.

Why the Evidence on PCOS and Muscle Mass Is More Mixed Than It Looks

A larger picture complicates the case control finding above. A systematic review and meta-analysis in Obesity Reviews pooled 45 observational studies and roughly 3,676 participants comparing lean body mass or fat free mass between women with PCOS and controls. It found that women with PCOS actually had slightly higher, not lower, total lean body mass than controls on average, and meta-regression analysis found no association between differences in total testosterone or HOMA-IR and differences in lean or fat free mass between groups. What did predict lean mass differences was body mass index: women with PCOS and a BMI of 25 or above had notably greater lean mass than controls, while those with a BMI under 25 showed no difference. The authors concluded plainly that obesity, not hyperandrogenism or insulin resistance, predicts skeletal muscle mass in PCOS.

Read together, these two studies are not necessarily contradictory, but they are measuring different things. The case control study looked at the percentage of body mass made up of muscle, a ratio that falls when fat mass rises even if absolute muscle mass stays the same or grows modestly. The meta-analysis looked at absolute lean mass in kilograms, which tracked overall body size and BMI rather than androgen levels or insulin resistance directly. Put another way, women with PCOS and higher BMI may carry somewhat more total muscle in absolute terms (partly as a natural consequence of carrying more body weight) while still having proportionally less muscle relative to their fat mass, which is exactly the pattern that defines sarcopenic obesity. The hormonal profile of PCOS may still matter for muscle quality, insulin sensitivity within muscle tissue, and functional strength, questions the existing pooled data could not fully answer since appendicular lean mass and strength results were too inconsistent across studies to combine statistically.

Practical Implications for Young Adults

For young men, the practical takeaway is not to seek out testosterone therapy on the basis of this evidence. The RCT discussed above studied clinically diagnosed testosterone deficiency under medical supervision, not otherwise healthy young men. What it does support is that the pathway from obesity to low testosterone to muscle loss is real and modifiable through weight and fat mass reduction, particularly visceral fat, which is one of the more direct levers available without medication. For young women with PCOS, the data suggest that managing insulin resistance and inflammation, through the same combination of resistance training and nutrition quality relevant to sarcopenic obesity generally, may matter more for muscle preservation than the androgen profile itself. Our complete guide to sarcopenic obesity in young adults covers the resistance training and nutrition approaches that address the downstream muscle and fat balance regardless of which hormonal pathway is contributing to it. Insulin resistance in particular does not act alone; it also blunts how muscle responds to protein and activity, a related mechanism discussed in our earlier piece on anabolic resistance and inactivity.

Limitations and What Remains Uncertain

Several caveats apply. The strongest RCT evidence on testosterone and lean mass comes from middle aged and older obese men, not young adults, so the magnitude of benefit in a 25 year old with early testosterone decline is inferred rather than directly demonstrated. The PCOS literature is genuinely mixed, and the meta-analysis's finding that androgens and insulin resistance did not predict absolute lean mass should temper any claim that correcting hormone levels alone would reverse sarcopenic obesity in PCOS. Muscle strength and quality, arguably more clinically relevant than muscle mass alone, were too inconsistently reported across the pooled PCOS studies to draw firm conclusions. Sex hormone effects on muscle likely also vary by ethnicity, baseline body composition, and disease severity, factors not fully captured in the study populations described here, which is part of why this project's screening of young Omani adults for metabolomic and genetic markers of sarcopenic obesity risk matters: population specific data, not just extrapolation from Western cohorts, is still needed.

Connecting Back to Sarcopenic Obesity

Hormonal pathways help explain why sarcopenic obesity can develop even in young adults who are not yet showing the age related muscle decline the condition was first described in. Falling testosterone tied to rising body fat in young men, and the insulin resistance and inflammation common in PCOS in young women, both plausibly accelerate the same fat gain, muscle loss cycle described in the ESPEN and EASO consensus definition of sarcopenic obesity as the coexistence of excess adiposity and low muscle mass or function. Neither pathway operates in isolation from lifestyle factors such as physical activity, protein intake, and sleep, which is exactly why the practical prevention steps on this site remain relevant regardless of a person's underlying hormonal profile.

References

This post is for general education and isn't medical advice. Speak with a healthcare provider about your individual hormonal health, and never start or stop a hormone therapy without medical supervision.

← Back to all posts